Imaging in Renal Cell Carcinoma Detection
Diagnostics · 23.09.2024 · 14 (18) · 2105
DOI: 10.3390/diagnostics14182105 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diagnostics, online erschienen am 23.09.2024. Verfasst von Dixon Woon und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Austin Health, Heidelberg, VIC 3084, Australia. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Imaging in renal cell carcinoma (RCC) is a constantly evolving landscape. The incidence of RCC has been rising over the years with the improvement in image quality and sensitivity in imaging modalities resulting in “incidentalomas” being detected. We aim to explore the latest advances in imaging for RCC.
Methods
A literature search was conducted using Medline and Google Scholar, up to May 2024. For each subsection of the manuscript, a separate search was performed using a combination of the following key terms “renal cell carcinoma”, “renal mass”, “ultrasound”, “computed tomography”, “magnetic resonance imaging”, “18F-Fluorodeoxyglucose PET/CT”, “prostate-specific membrane antigen PET/CT”, “technetium-99m sestamibi SPECT/CT”, “carbonic anhydrase IX”, “girentuximab”, and “radiomics”. Studies that were not in English were excluded. The reference lists of selected manuscripts were checked manually for eligible articles.
Results
The main imaging modalities for RCC currently are ultrasound, computed tomography (CT) and magnetic resonance imaging (MRI). Contrast-enhanced US (CEUS) has emerged as an alternative to CT or MRI for the characterisation of renal masses. Furthermore, there has been significant research in molecular imaging in recent years, including FDG PET, PSMA PET/CT, 99mTc-Sestamibi, and anti-carbonic anhydrase IX monoclonal antibodies/peptides. Radiomics and the use of AI in radiology is a growing area of interest.
Conclusions
There will be significant change in the field of imaging in RCC as molecular imaging becomes increasingly popular, which reflects a shift in management to a more conservative approach, especially for small renal masses (SRMs). There is the hope that the improvement in imaging will result in less unnecessary invasive surgeries or biopsies being performed for benign or indolent renal lesions.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Austin Health, Heidelberg, VIC 3084, Australia.
- Department of Surgery, The University of Melbourne, Melbourne, VIC 3010, Australia.
- Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
- Department of Urology, Royal Melbourne Hospital, Parkville, VIC 3052, Australia.
ORCID-Profile: Shane Qin, Nathan Lawrentschuk
Zitieren
APA
Woon, D., Qin, S., Al-Khanaty, A., Perera, M., & Lawrentschuk, N. (2024). Imaging in Renal Cell Carcinoma Detection. Diagnostics, 14(18), 2105. https://doi.org/10.3390/diagnostics14182105
Vancouver
Woon D, Qin S, Al-Khanaty A, Perera M, Lawrentschuk N. Imaging in Renal Cell Carcinoma Detection. Diagnostics. 2024;14(18):2105. doi:10.3390/diagnostics14182105
BibTeX
@article{Woon2024,
author = {Woon, Dixon and Qin, Shane and Al-Khanaty, Abdullah and Perera, Marlon and Lawrentschuk, Nathan},
title = {Imaging in Renal Cell Carcinoma Detection},
journal = {Diagnostics},
year = {2024},
volume = {14},
number = {18},
pages = {2105},
doi = {10.3390/diagnostics14182105}
}
EUVIMED